Results 11 to 20 of about 656,371 (370)

Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913 [PDF]

Haematologica, 2021
Early recognition of Philadelphia-like (Ph-like) acute lymphoblastic leukemia (ALL) cases could impact on the management and outcome of this subset of B-lineage ALL.
Ansuinelli M., Apicella V., Bassan R., Cafforio L., Cairoli R., Candoni A., Canichella M., Capria S., Cattaneo C., Cavalli M., Cerrano M., Chiaretti S., Crea E., de Fabritiis P., Di Raimondo F., Elia L., Fazi P., Foa R., Fracchiolla N., Guarini A., la Starza R., Lauretti A., Mattei D., Mecucci C., Messina M., Papayannidis C., Petroni G. A., Piciocchi A., Pierini V., Puzzolo M. C., Rambaldi A., Santoro A., Spinelli O., Starza I. D., Taherinasab A., Vitale A.   +35 more
core   +2 more sources

Minimal Residual Disease in Melanoma

Seminars in Surgical Oncology, 2001
AbstractA number of specific genes encoding for melanosomal proteins are selectively expressed in melanocytes and melanomas. For detection of circulating melanoma cells, the expression of the tyrosinase gene is most widely used. Several cohorts of melanoma patients from single institutions have been analyzed by various research groups for the presence ...
Uwe Reinhold, Wolfgang Tilgen
openalex   +4 more sources

Cellular dormancy in minimal residual disease following targeted therapy

Breast Cancer Research, 2021
Background Breast cancer mortality is principally due to tumor recurrence, which can occur following extended periods of clinical remission that may last decades.
Jason R. Ruth, Dhruv K. Pant, Tien-chi Pan, Hans E. Seidel, Sanjeethan C. Baksh, Blaine A. Keister, Rita Singh, Christopher J. Sterner, Suzanne J. Bakewell, Susan E. Moody, George K. Belka, Lewis A. Chodosh   +11 more
doaj   +2 more sources

Minimal Residual Disease in Hematological Malignancies [PDF]

Acta Haematologica, 2004
Accessible online at: www.karger.com/aha Do you prefer quality to quantity? This question has been asked for many years. It is well known that mathematics is the science of pure quantity but what about medicine? For many years, counting cells and identifying them by microscopic inspection have determined the number of normal or abnormal cells in ...
Pia Raanani, Andreas Hochhaus
openalex   +5 more sources

Minimal Residual Disease Assessment in Multiple Myeloma Patients: Minimal Disease With Maximal Implications

Frontiers in Oncology, 2022
Multiple Myeloma (MM), the second most common hematologic malignancy, has been the target of many therapeutic advances over the past two decades. The introduction of novel agents, such as proteasome inhibitors, immunomodulatory drugs, and monoclonal ...
Charalampos Charalampous, Taxiarchis Kourelis   +1 more
doaj   +1 more source

Circulating Tumor DNA Minimal Residual Disease Detection of Non-Small-Cell Lung Cancer Treated With Curative Intent.

Journal of Clinical Oncology, 2022
Circulating tumor DNA (ctDNA) minimal residual disease (MRD) is a powerful biomarker with the potential to improve survival outcomes for non-small-cell lung cancer (NSCLC).
B. Pellini, A. Chaudhuri
semanticscholar   +1 more source

Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer

Clinical Cancer Research, 2021
Purpose: Detection of persistent circulating tumor DNA (ctDNA) after curative-intent surgery can identify patients with minimal residual disease (MRD) who will ultimately recur.
A. Parikh, E. V. Van Seventer, G. Siravegna, A. Hartwig, A. Jaimovich, Yupeng He, K. Kanter, M. Fish, Kathryn Fosbenner, B. Miao, S. Phillips, John H Carmichael, Nihaarika Sharma, Joy Jarnagin, I. Baiev, Yojan S. Shah, I. Fetter, Heather A. Shahzade, Jill N. Allen, L. Blaszkowsky, Jeffrey W. Clark, J. Dubois, J. Franses, B. Giantonio, L. Goyal, S. Klempner, R. Nipp, E. Roeland, D. Ryan, C. Weekes, J. Wo, T. Hong, L. Bordeianou, C. Ferrone, M. Qadan, H. Kunitake, D. Berger, R. Ricciardi, J. Cusack, V. Raymond, Amirali Talasaz, G. Boland, R. Corcoran   +42 more
semanticscholar   +1 more source

Liquid BIOpsy for MiNimal RESidual DiSease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS)—a personalised circulating tumour DNA analysis in head and neck squamous cell carcinoma

British Journal of Cancer, 2022
Head and neck squamous cell carcinoma (HNSCC) remain a substantial burden to global health. Cell-free circulating tumour DNA (ctDNA) is an emerging biomarker but has not been studied sufficiently in HNSCC.
S. Flach, K. Howarth, S. Hackinger, C. Pipinikas, Peter J. I. Ellis, K. McLay, G. Marsico, T. Forshew, C. Walz, C. Reichel, O. Gires, M. Canis, P. Baumeister   +12 more
semanticscholar   +1 more source

Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA

Nature Biotechnology, 2021
Circulating tumor-derived DNA (ctDNA) is an emerging biomarker for many cancers, but the limited sensitivity of current detection methods reduces its utility for diagnosing minimal residual disease.
D. Kurtz, Joanne Soo, Lyron Co Ting Keh, S. Alig, J. Chabon, B. Sworder, A. Schultz, M. Jin, F. Scherer, A. Garofalo, C. Macaulay, Emily G. Hamilton, Binbin Chen, M. Olsen, J. Schroers-Martin, A. Craig, E. Moding, M. S. Esfahani, C. Liu, U. Dührsen, A. Hüttmann, R. Casasnovas, J. Westin, M. Roschewski, W. Wilson, G. Gaidano, D. Rossi, M. Diehn, Ash A. Alizadeh   +28 more
semanticscholar   +1 more source

Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual Disease.

Cancer Discovery, 2021
Growing evidence demonstrates that circulating tumor DNA (ctDNA) minimal residual disease (MRD) following treatment for solid tumors predicts relapse.
E. Moding, B. Nabet, Ash A. Alizadeh, M. Diehn   +3 more
semanticscholar   +1 more source